uniQure N.V. — Cyborg Score 4/10

Strategic Profile

In 2025, uniQure presented compelling 36-month clinical data from AMT-130 demonstrating its potential to become a first disease-modifying therapy for people living with Huntington's disease. However, the FDA reversed its stance on using external controls for AMT-130's approval, creating near-term uncertainty. The company maintains a robust cash position with approximately $622.5 million in cash to support operations into the second half of 2029, with its product pipeline targeting hemophilia, Huntington's disease, and cardiovascular diseases.

Cyborg Score Rationale

Despite mixed results, the company holds a strong cash position of $622.5 million, projected to sustain operations into the second half of 2029. However, warning signs include an Altman Z-Score of -0.88, placing the company in the distress zone, and insider selling activity. Recent regulatory setbacks on its lead Huntington's program create significant execution risk despite strong clinical data.

Top Insights

• Presented compelling 36-month AMT-130 data for Huntington's disease but has not reached FDA alignment on approval pathway
• Revenue declined 40.6% year-over-year to $16.1 million in 2025
• Gene therapy for hemophilia B represents major milestone in genomic medicine after more than a decade of development
• P/S ratio of 42.68 suggests potential overvaluation relative to current revenue generation

Named Competitors

• Zolgensma — Gene therapy for spinal muscular atrophy
• Luxturna — Gene therapy for inherited retinal dystrophy
• Gene therapies for various indications — Cell and gene therapy company for severe genetic diseases

Recent Developments

• (March 2026) Reported 2025 financial results with strong cash position; held FDA Type A meeting on AMT-130
• (January 2026) FDA provided feedback reversing stance on external controls for AMT-130 approval pathway
• (September 2025) Presented pivotal topline data from Phase 1/2 AMT-130 study meeting primary endpoints

Open the full interactive uniQure N.V. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.